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Abstract
Gene transfer of drug resistance (CTX-R) genes can be used to protect the hematopoietic system from the toxicity of
anticancer chemotherapy and this concept recently has been proven by overexpression of a mutant O6-methylguanine-
methyltransferase in the hematopoietic system of glioblastoma patients treated with temozolomide. Given its protec-
tion capacity against such relevant drugs as cytosine arabinoside (ara-C), gemcitabine, decitabine, or azacytidine and
the highly hematopoiesis-specific toxicity profile of several of these agents, cytidine deaminase (CDD) represents
another interesting candidate CTX-R gene and our group recently has established the myeloprotective capacity of
CDD gene transfer in a number of murine transplant studies. Clinically, CDD overexpression appears particularly
suited to optimize treatment strategies for acute leukemias and myelodysplasias given the efficacy of ara-C (and to
a lesser degree decitabine and azacytidine) in these disease entities. This article will review the current state of the art
with regard toCDD gene transfer and point out potential scenarios for a clinical application of this strategy. In addition,
risks and potential side effects associated with this approach as well as strategies to overcome these problems will
be highlighted.
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Myeloprotective Gene Therapy by Overexpression
of Drug Resistance Genes in Hematopoietic
Stem Cells
Given their ability to self-renew, proliferate extensively, and differen-
tiate into all the different mature cells of the lymphohematopoietic
system, hematopoietic stem cells (HSCs) have been considered
a particularly promising target population since the beginning of
gene therapeutic activities in the mid-1980s. The attractivity of
HSCs for gene therapy approaches is further supported by their easy
accessibility by bone marrow biopsy or granulocyte-colony stimulat-
ing factor (G-CSF) mobilization and leukapheresis, as well as clearly
defined procedures for their storage and transplantation. First proof
of principle for HSC gene transfer in the murine system was estab-
lished as early as the mid-1980s [1–3]; however, it took until the begin-
ning of the current millennium that HSC gene therapy was transferred
successfully to the clinical setting. So far, HSC gene therapy has been
used in particular for the treatment of congenital diseases with manifes-
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tation in the hematopoietic system such as severe X-linked combined
immunodeficiency, adenosine deaminase deficiency, chronic granu-
lomatous disease, or more recently Wiskott-Aldrich syndrome and
X-linked adrenoleukodystrophy [4,5].
Another potentially attractive strategy to put HSC gene therapy to
clinical use is the protection of the lymphohematopoietic system from
the side effects of anticancer chemotherapeutic drugs by (over)expression
of drug resistance (CTX-R) genes. A number of such CTX-R genes have
been identified, which according to their subcellular localization can
roughly be classified into three groups: 1) membrane-associated pump
or pore proteins, 2) cytoplasmic proteins involved in drug or prodrug
metabolism, and 3) nuclear proteins associated with DNA repair.
While some of these CTX-R genes primarily have been investigated
in vitro, for others the potential to protect the lymphohematopoietic
system from the associated cytotoxic agents has been firmly established
in murine as well as large animal models (see Table 1 and for review
[6–8]). Myeloprotective properties in particular have been demon-
strated for mutants of the gene coding for the DNA repair protein O6-
methylguanine DNA-methyltransferase (mutMGMTP140K), the
multidrug resistance 1 (MDR1) gene coding for the cellular efflux pump
p-glycoprotein, mutant forms of dihydrofolate reductase (mutDHFR),
and cytidine deaminase (CDD). While the antileukemic properties of
mutMGMT-associated drugs are limited, in particular MDR1 or
CDD represents highly interesting CTX-R genes in the context of acute
leukemias and myelodysplasias given their myeloprotective potential in
the context of anthracyclines (and to a lesser extent etoposide) or cytidine
analog therapy. Overexpression of mutDHFR, aldehyde dehydroge-
nase, or multidrug resistance–related protein and hypoxanthine-guanine
phosphoribosyl transferase knockdown protecting from methotrexate,
cyclophosphamide, or anthracyclines, and thioguanine, respectively,
represent further applications of CTX-R genes with potential relevance
in leukemia therapy.
Currently, the clinicallymost advancedCTX-R gene transfer strategy for
myeloprotection applies MGMT point mutants resistant to the specific
wild-type MGMT inhibitor O6-benzylguanine (BG). MutMGMT gene
transfer followed by combined BG/1,3-bis(2-chloroethyl)-1nitrosourea
(BCNU) or BG/temozolomide chemotherapy has proven highly effi-
cacious for myeloprotection as well as in vivo selection in murine and
several large animal models [8–10]. Furthermore, a recent clinical trial
has demonstrated efficient myeloprotection and in vivo enrichment of
geneticallymodified cells followingmutMGMTgene therapy in a cohort
of glioblastoma patients demonstrating progression-free survival for
more than 2 years in individual patients [11]. However, the clinical
indications for mutMGMT-associated drugs such as temozolomide- or
chloroethylnitrosourea-type agents are rather limited, and apart
from brain tumors, these drugs are only considered standard therapy
in malignant melanomas [12]. In addition, both drugs suffer from
substantial nonhematopoietic toxicities and a considerable mutagenic
potential [13].
MutDHFR has been investigated for myeloprotective gene transfer
strategies since the late 1980s and significant protection has been shown
in vitro as well as in animal models, and even effective in vivo selection
Table 1. Drug Resistance Genes and Their Potential Use in Chemotherapy.
Gene and Localization Resistance to Mode of Action Level of Evidence References
Plasma membrane
MDR1* (P-glycoprotein 1) Anthracyclines, vinca alkaloids,
taxoids, etoposide
Efflux of drugs Human xenotransplant model
(human clinical trial)†
[17,74]
Multidrug resistance–related protein‡ Anthracyclines, vinca alkaloids,
taxoids, etoposide
Efflux of drugs Murine in vivo model [75]
hENT2 nucleoside transporter Trimetrexate, tomudex
(plus NBMPR§)
Nucleoside transporter Murine in vivo model [76]
ABCG2¶ Anthracyclines, taxoids Efflux of drugs (side population) Human cell lines [77]
Cytoplasmic
DHFR Methotrexate, trimetrexate Mutant form is unaffected by the drug Large animal model [78]
CDD ara-C, gemcitabine Detoxification of prodrug Murine in vivo model [39]
Aldehyde dehydrogenase Cyclophosphamide Detoxification of prodrug Murine in vivo model [79]
Glutathione S -transferase Cyclophosphamide, anthracyclines Detoxification of prodrug Murine in vivo model [80]
Thymidylate synthase 5-Fluorouracil, tomudex Mutant form is unaffected by the drug Murine primary cells [81]
Ribonucleotide reductase Hydroxyurea Mutant form is unaffected by the drug Murine in vivo model [82,83]
Nuclear
MGMT# Chloroethylnitrosoureas and
decarbazine derivatives
(plus BG)
Removal of O6 adducts from the DNA Human clinical trial [11]
APN1(yeast)/APE(human)** Bleomycin and ionizing radiation Repairs AP sites, oxidative damage, and
alkylation damage in DNA
Human cell lines [84,85]
8-Oxoguanine glycosylase/Fapy-DNA glycosylase ThioTEPA Removal of alkylated bases in DNA Murine primary cells/murine
in vivo model
[86]
Superoxide dismutase Anthracyclines and paraquat Protection against oxidative damage Human cell lines [75,87]
Topoisomerase I Camptothecin DNA repair function Human cell lines [78]
Topoisomerase II Anthracyclines and etoposide DNA repair function Human cell lines [79]
HPRT†† 6-Thioguanine Ribosylation of purine analogs Murine in vivo model [88]
*Multidrug resistance gene.
†Failed due to technical problems.
‡Multidrug resistance–related protein coding gene.
§Nitrobenzylmercaptopurine riboside.
¶ATP-binding cassette subfamily G member 2 (also known as breast cancer resistance protein).
#O6-Methylguanine DNA-methyltransferase.
**Apurinic/apyrimidinic endonuclease.
††Hypoxanthine-guanine phosphoribosyl transferase.
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of mutDHFR-transduced cells has been achieved in the murine model
[14]. However, mutDHFR-induced myeloprotection is restricted to
the small group of antifolate cytotoxic drugs such as methotrexate or
trimetrexate. Although these agents induce considerable lymphotoxicity
and are routinely administered for immunosuppression in a large number
of diseases, generalized myelotoxicity rarely is encountered as the
dose-limiting toxicity of folate antagonists, thus questioning the clin-
ical relevance of mutDHFR for myeloprotection at least when used
on its own.
MDR1, however, confers resistance against a wide variety of clin-
ically highly relevant chemotherapeutic agents such as anthracyclines,
epipodophyllotoxins, taxoids, or vinca alkaloids, of which at least the
first three groups are associated with profound and frequently dose-
limiting myelosuppression. Significant protection from the toxicity of
several of these agents upon MDR1 overexpression has been demon-
strated for murine as well as human hematopoietic cells in vitro and in
animal models [15,16], although effective transgenic MDR1 expres-
sion in clinical studies has been problematic [17,18]. These studies
were performed more than a decade ago, however, and in the choice
of γ-retroviral vectors as well as transduction protocols clearly do not
represent the current state of the art of HSC gene transfer technology.
Thus, at present the clinical potential of MDR1 in myeloprotective
gene therapy strategies remains poorly defined.
CDD Gene Transfer and Protection from
Myelosuppression Induced by Ara-C
and Other Cytidine Analogs
CDD (EC 3.5.4.5) at the moment probably represents the most rele-
vant CTX-R gene for myeloprotection in the context of acute leukemia
or myelodysplasia therapy. CDD is an enzyme involved in the nucleo-
tide salvage pathway and catalyzes the deamination of cytidine and
deoxycytidine to uridine and deoxyuridine, respectively, and protects
cells from the clinically highly relevant cytotoxic cytidine analogs cyto-
sine arabinoside (1-β-D-arabinofuranosylcytosine, ara-C), gemcitabine
(2′,2′-difluorodeoxycytidine), decitabine (5-aza-2-deoxycytidine), and
azacytidine (5-azacytidine; see Figure 1). These nucleoside analogs con-
stitute prodrugs that after entry into the cell and phosphorylation to
the triphosphate state by the nucleotide salvage pathway exert their
specific cytotoxic activities during or after incorporation into the DNA
where they interfere with DNA strand elongation, replication, or repair
processes [19] (see Figure 2). In particular, ara-C has been used clini-
cally for extended time periods and has established itself as the most
effective single agent in the treatment of acute myeloid leukemias
(AMLs). Importantly, ara-C has a predominantly hematopoietic toxic-
ity profile and, when given at low to intermediate doses, hematotoxicity
represents the most frequent side effect described. This toxicity profile
may be related to the low CDD expression levels observed in hemato-
poietic progenitor/stem cells [20], while mature myeloid cells and in
particular granulocytes represent the cells with the highest endogenous
CDD expression within the hematopoietic system [21]. The notion of
CDD as a resistance factor to ara-C goes back to 1971, when Steuart
and colleagues described high levels of CDD in the leukemic blasts of
AML patients relapsing after ara-C treatment [22]. This correlation be-
tween CDD activity in AML blasts and clinical response to ara-C therapy
has been confirmed by several groups, and in particular, pretreatment
CDD activity has been described to predict therapeutic outcome [21].
These data meanwhile have triggered a whole series of studies aiming
at CDD overexpression for myeloprotection in the context of cytidine
analog application (overview given in Table 2).
Early Cell Line and Murine In Vitro Studies
on CDD-Mediated Drug Resistance
The first studies to describe a protective effect of CDD (over)expression
on cytidine analog–induced cytotoxicity used murine fibroblast cell
lines transfected with the cDNA of human (h)CDD and were reported
in 1996 [20,23]. While these studies varied considerably with regard to
the degree of CDD overexpression (50- to 2.5-fold) and ara-C resis-
tance (100- to 3.0-fold), they clearly established a gene dose-dependent
cytoprotective effect of transgenic CDD overexpression without obvi-
ous transgene-related toxicity. These observations were followed by
studies employing γ-retroviral gene transfer technology to express
hCDD in 3T3 fibroblasts, hematopoietic CCRF-CEM cells, as well
as primary murine bone marrow cells [24,25]. While constitutive over-
expression of hCDD resulted in a 2- to 10-fold increased ara-C resistance
in CCRF-CEM or 3T3 cells and CDDwas confirmed as the functional
basis for the observed ara-C resistance by complete reversibility of the
effect by the CDD-specific, competitive inhibitor tetrahydrouridine,
an approximately 1.000-fold increased ara-C resistance was described
in bone marrow–derived primary murine clonogenic progenitor cells
[24,25]. CDD-mediated ara-C resistance was further confirmed by
a number of in vitro studies all applying γ-retroviral gene transfer
technology to transduce fibroblasts, hematopoietic cell lines, and pri-
mary murine hematopoietic cells. These studies also extended CDD-
meditated drug resistance to other cytidine analog–type cytotoxic
Figure 1. Cytidine analog–type cytotoxic drugs for the treatment of AML. Chemical structure of cytidine and its cytotoxic drug analogs
ara-C, gemcitabine, decitabine, and azacytidine.
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drugs, such as gemcitabine or azacytidine [26–29], and established
in vitro selection of CDD-modified cells with up to 99% enrichment
of transgene-positive cells by ara-C, gemcitabine, or azacytidine expo-
sure [26,30]. However, protection conferred by CDD overexpression
in these studies varied considerably, most likely due to substantial
differences in endogenous CDD expression levels in different target
tissues and/or suboptimal gene transfer rates.
CDD-Mediated Drug Resistance in Human In Vitro Models
For clinical application of CDD-mediated myeloprotection, stable
CDD overexpression in human hematopoietic progenitor/stem cells
clearly represents a crucial prerequisite. However, efficient gene transfer
into primitive hematopoietic cells traditionally has been much harder to
achieve in the human compared to the murine system and it took some
time until the hurdles responsible for this discrepancy such as insuffi-
cient quality and purity of starting populations or low transduction
efficiency due to insufficient transduction protocols for human HSCs
could be overcome by meticulous studies performed in vitro as well
as in murine, canine, and nonhuman primate models. Consequently,
optimized transduction strategies nowadays apply specific cytokine
combinations, fibronectin (retronectin) coculture, or vector particles
pseudotyped with suitable envelope proteins [31–35]. Thus, it took
until 2005 to establish clear evidence for the protection of primary
human hematopoietic cells from cytidine analog–induced toxicity by
CDD gene transfer. Transduction of umbilical cord– or peripheral
Figure 2. Metabolism of cytidine and cytidine analog–type agents. (A) Deamination of cytidine to uridine by CDD as an alternative to
phosphorylation of the molecule by uridine kinase and, more importantly, deoxycytidine kinase to CMP as a first step in the nucleotide
salvage pathway. Subsequently, the CMP and cytidine di-phosphate (CDP) kinases phosphorylate CMP to its active counterpart cytidine
triphosphate to be incorporated into the DNA. (B) Similarly, cytidine analogs such as ara-C either get inactivated by the CDD to Ara-U or are
phosphorylated to their active triphosphate form, which upon integration into the DNA exert their various cytotoxic functions.
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blood–derived CD34+ stem/progenitor cells with a spleen focus-forming
virus (SFFV)–based γ-retroviral vector harboring the hCDD-cDNA re-
sulted in pronounced CDD overexpression and a significantly increased
resistance of transduced progenitor cells to ara-C and gemcitabine as
determined by the effect on the clonogenic growth of progenitor cells
differentiated along the erythroid or myeloid lineage in methylcellulose-
based assays. Furthermore, significant in vitro selection of CDD-
transduced primary human clonogenic progenitor cells was observed
upon culture of the cells in the presence of ara-C for 4 days [36].
In Vivo Efficacy of CDD Gene Transfer in
Murine Bone Marrow Transplant Models
While experiments performed in the late 1980s only demonstrated
moderately increased ara-C resistance in clonogenic progenitors
harvested from the bone marrow of animals transplanted with CDD-
transduced HSCs and no convincing evidence of in vivo myelo-
protection was obtained [27], the technical shortcomings associated
with these early studies meanwhile have been overcome. In a more
recent study, not only stable and long-term expression of CDD in
the hematopoietic system of recipients of CDD-transduced bone
marrow cells has been achieved but constitutive overexpression of
CDD in the murine lymphohematopoietic system was also demon-
strated to confer significant myeloprotection in the context of ara-C
therapy. Following short-term high-dose [500 mg/kg, days 1–4;
intraperitoneal (i.p.)] ara-C application, granulocyte nadirs of 2.9 ±
0.6/nl versus 0.7 ± 0.1/nl and thrombocyte nadirs of 509 ± 147/nl
versus 80 ± 9/nl for the CDD versus the control group were demon-
strated [37], and similar differences were observed with prolonged
low-dose (60 mg/kg, days 1–10; i.p.) treatment [38] (see Figure 3).
Moreover, animals overexpressing CDD in their hematopoietic system
were also protected from otherwise lethal gemcitabine doses and a 24-
to 149-fold increased cytoplasmic CDD activity was observed in bone
marrow and spleen cells of primary recipients [37]. While these data
reflect the excellent expression levels achievable with SFFV/murine
embryonic stem cell virus (MESV)-based vectors in hematopoietic cells,
these very high levels may also have contributed to the transgene-related
toxicities observed in these studies (see below). Significant in vivo
myeloprotection was also demonstrated for tet-regulated overexpression
of CDD [39], an approach that may be suited to circumvent CDD-
induced transgene toxicity (see below).
Interestingly, despite the profound myeloprotective effects ob-
served and in clear contrast to the data obtained from in vitro systems,
no long-term in vivo selection of CDD-overexpressing cells was ob-
served in these studies [37,38]. This suggests that the myeloprotective
effect exerted by CDD is achieved primarily on the level of progenitor
or more mature cells rather than stem cells. Indeed, relatively moder-
ate stem cell toxicity of ara-C has been described [40], an observation
readily explained by the relative quiescence of repopulating HSCs
and the S-phase–specific activity of ara-C. Such a “stem cell–sparing”
activity of ara-C is also suggested by its clinical toxicity profile. Here,
after high-dose ara-C application (3 g/m2, six to eight doses), a pro-
found and long-lasting myelosuppression nearly inevitably is followed
by a complete hematopoietic reconstitution. However, repetitive low
to intermediate-dose ara-C application has been reported to increase
HSC cycling and thus ara-C susceptibility of HSCs [41]. Transfer of
this strategy to a murine CDD gene transfer/HSC transplant model
resulted in significant in vivo selection with an up to six-fold increase of
CDD-transduced cells in the peripheral blood, when 30 to 60 mg/kg
ara-C was administered repetitively for 10 to 20 days i.p. However, this
effect was only transient, suggesting selection on the level of early pro-
genitor cells rather than true HSCs [38].
Studies on Combined Gene Transfer of CDD and
Other CTX-R Genes
Given the fact that modern anticancer chemotherapeutic regimen
nearly inevitably combine a number of cytotoxic drugs to reduce agent-
specific toxicities and delay the emergence of therapy-resistant tumor
cells, simultaneous (over)expression of CTX-R genes appears as a
suitable strategy to respond to this situation. With respect to CDD
in particular, combinations with mutDHFR have been investigated
using moloney murine leukemia virus (MMLV)-based γ-retroviral
backbones to express a mutDHFR/CDD fusion protein. In these
studies, combined mutDHFR and CDD expression resulted in signifi-
cant protection against methotrexate as well as ara-C toxicity [42,43] and
successful treatment of human lymphoma cells has been reported in a
Table 2. Overview of CDD in Myeloprotective Gene Therapy.
Model Cell Type Gene Expression Systems Year References
In vitro Cell lines 3T3 fibroblast Retroviral Constitutive 1996, 1998 [24,25,28]
CCRF-CEM (hematopoietic) Retroviral Constitutive 1996 [24]
Various Plasmid (cDNA) Constitutive 1996 [20]
Fibroblasts Plasmid (cDNA) Constitutive 1996 [23]
NIH 3T3 fibroblast1,2 Retroviral Constitutive 1998 to 2000 [42,43,45]
WEHI-3 (hematopoietic) Retroviral Constitutive 1999 [29]
L1210 (hematopoietic) Retroviral Constitutive 2001 [26]
Human lung carcinoma cells Retroviral Constitutive 2002 [30]
32D (hematopoietic) Lentiviral (third generation) Inducible 2012 [39]
Primary mouse Bone marrow cells (BMCs) Retroviral Constitutive 1996 to 2001 [25,26,29]
BMCs1 Retroviral Constitutive 1998 to 1999 [42,43]
Bone marrow stromal cells Retroviral Constitutive 2002 [30]
HSCs Lentiviral (third generation) Inducible 2012 [39]
Primary human Cord blood– and peripheral blood–derived
progenitor cells
Retroviral Constitutive 2005 [36]
In vivo Primary mouse Hematopoietic BMCs Retroviral Constitutive 1998 [27]
BMCs1 Retroviral Constitutive 2004 [44]
HSCs Retroviral Constitutive 2006, 2012 [37,38]
HSCs Lentiviral (third generation) Inducible 2012 [39]
1,2Combinations with other CTX-R genes: 1mutDHFR, 2glutathione S -transferase A3.
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“humanized”murine xenotransplant model applying CDD/mutDHFR
co-transduced murine bone marrow cells to protect the hematopoietic
system from combined ara-C plus methotrexate chemotherapy [44].
CDD overexpression has also been combined with expression of gluta-
thione S-transferase A3 to protect from combined nitrogen mustard/
ara-C treatment, although this concept never exceeded the phase of
in vitro cell line studies [45].
Predictions from Preclinical Studies for
Clinical Application Scenarios
In general, in vitro studies employing cell lines or murine clonogenic
progenitor growth have demonstrated CDD-mediated ara-C resistance
at concentrations of 10 to 500 nM [29]. The only exception was an
early study reporting resistance to ara-C doses of up to 50 μM [25],
but also these authors later describe resistance only in the aforemen-
tioned dose range [27]. CDD-mediated resistance to ara-C doses rang-
ing from 60 to 500 nM was also observed for primary human
clonogenic cells [36]. These similarities come to no surprise, as for both
human and murine progenitor/stem cells low CDD activity has been
demonstrated [20], and in both species, the hematopoietic system rep-
resents a critical target organ for ara-C and cytidine analog toxicity.
These data strongly implies that in the clinical situation protection of
hematopoietic cells from conventionally dosed ara-C should be possible.
Ara-C conventionally is administered at doses of 100 to 200mg/m2 given
consecutively for 3 to 7 days, and when delivered as continuous infusion,
this result in steady-state plasma concentrations of 100 to 1200 nM.
Currently, the most reliable parameter to predict ara-C cytotoxicity,
within certain limits, is the product of exposure time and drug con-
centration. This product was clearly exceeded in studies demonstrating
myeloprotection in clonogenic assays applying ara-C doses of up to
500 nM (and in our recent studies with advanced lentiviral vectors even
up to 600 nM; own unpublished data) for 10 to 14 days. Furthermore,
the data from in vivo transplant studies [37] suggests that protection
in the clinical situation should also be possible from high-dose ara-C
application (3 g/m2 i.v., six to eight doses at 12-hour intervals). For the
standard patient (75 kg, 1.75-m2 surface area), this schedule results in a
total dose of approximately 0.6 g ara-C/kg body weight administered
over a 4-day period, while in the murine transplant studies protection
from up to 2 g/kg ara-C was demonstrated. These calculations should
be addressed with some caution, however, as different application
schedules (1× daily i.p. in the murine model versus 2× daily i.v. in the
clinical situation) have to be taken into account.
Clinical Application of CDD Gene Therapy
Application of CDD Gene Transfer in the Treatment of
Acute Leukemias and Myelodysplasias
Clearly, treatment of high-risk disease states in a post-autologous/
allogeneic HSC transplantation setting represents the most suitable
clinical scenario for the initial application of CDD gene therapy in
these disease entities. In this situation, effective therapies to decrease
post-HSC relapse are clearly needed [46]; however, dose-intensive
consolidation or maintenance therapy with ara-C, azacytidine, or dec-
itabine frequently is associated with severe myelosuppression leading to
Figure 3. Myeloprotection by CDD gene transfer in an in vivo murine transplant model. (A) Schematic overview of the gene transfer
model, vector constructs, and chemotherapy application schedule used. Nadir levels of (B) peripheral blood granulocyte and (C) thrombo-
cyte counts (mean± SEM; n=5) following high-dose (4 × 500mg/kg, i.p., days 1–4) or prolonged low-dose (10× 60mg/kg, i.p., days 1–10)
ara-C treatment are given. *P< .05 and **P< .01 denote significant differences by Student’s t test (data compiled from Rattmann et al. [37]
and Brennig et al. [38]; CDD: cytidine deaminase; IRES: internal ribosomal entry site; LTR: long terminal repeat; EGFP: enhanced green
fluorescent protein).
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dose adjustments and consecutively inferior therapeutic results. This
may be prevented by overexpression of CDD either alone or in com-
bination with other CTX-R genes before cytidine analog therapy. As
especially for patients with complex aberrant karyotypes, early allo-
geneic HSC appears to be beneficial [47]. CTX-R gene transfer could
be incorporated into relatively early phases of treatment for these high-
risk patients to decrease side effects and thereby potentially increase
dose intensity and outcome of subsequent cytidine analog chemo-
therapy. In addition to ara-C, there currently is an increasing interest
to evaluate also azacytidine in the post-allo HSC transplantation situa-
tion for relapsed disease. While azacytidine exerts considerable activity
in this situation, again cytopenias giving rise to bleeding and infections
represent the main side effects [47–49]. Furthermore, CDD gene trans-
fer in the context of HSC transplantation following reduced intensity
conditioning (RIC) may be an option for elderly or less fit patients to
receive adequate chemotherapy doses. In this situation, the reduction of
hematotoxic side effects may lead to increased tolerability and sub-
sequently better treatment compliance, which otherwise is a significant
problem in this patient population [50]. Refractory or relapsing disease
in acute leukemias has been associated with the survival of leukemic
stem cells (LSCs) [51,52] as defined by the xenotransplantation model
[53,54]. However, the activity of ara-C in leukemia stem cells has been
questioned [55]. As this may be related to the relative quiescent state of
LSCs in the “LSC-niche” [56,57], cell cycle–promoting application
schedules of ara-C such as prolonged low-dose treatment or combi-
nations with cycle-inducing cytokines such as G-CSF or interferons
[58,59] may be preferred in this context.
CTX-R Gene Combinations
As stated above, modern CTX regimen usually combine cytotoxic
agents to improve efficacy and delay therapy resistance. This may be
counteracted by the combined use of CTX-R genes, an approach
clearly feasible with current gene transfer vector technology [60].
Considering the dominant role of cytidine analogs in AML and
high-risk myelodysplasia therapy and the fact that ara-C/anthracycline
combinations such as the classical “3 + 7” combinations, TAD9, HAM,
or Flac-Ida [61] still represent a cornerstone of first- and second-line
anti-AML chemotherapies and are associated with a profound and
long-lasting myelosuppression considerably contributing to therapy-
related morbidity and occasionally even mortality, MDR1 appears
as a natural combination partner for CDD gene therapy in these
disease entities.
In addition, given the success in a recent phase I study in glioblas-
toma patients [11],mutMGMT represents another potential combination
partner for CDD gene transfer. This will allow not only for myelopro-
tection from O6-alkylating agents but also for effective in vivo selection
of drug-resistant HSCs. Though diseases responsive to ara-C as well as
chloroethylnitrosoureas or triazene derivatives are quite rare, one context
to exploit the CDD/MGMT combination (with a potential add-on
of MDR1) may be salvage therapy of aggressive lymphomas based
Figure 4. Regulation of transgene expression by doxycycline-induced (Tet-on) and miRNA-mediated expression systems. (A) The doxy-
cycline (dox; also known as tetracycline, Tet)–controlled reverse transactivator protein (rTA) represents a Tet-repressor protein fused to three
minimal VP16 activation domains of the herpes simplex virus. In the absence of dox, transgene expression (as of the hCDD) is inhibited,
whereas in the presence of dox, rTA binds to the Tet-responsive element (TRE) and activates transgene transcription from the cytomega-
lovirus (CMV) minimal promoter (PminCMV). (B) Optimized self-inactivating (SIN) lentiviral vector backbone for cell type–specific transgene
(hCDD) expression. The vector carries specific miRNA target sites (here for miRNA-150) fused to the transgenic cDNA. Transgene expres-
sion is suppressed in cells expressing the correspondingmiRNA, as themiRNAwill bind to the respective target site (here mir150T) and lead
to transgene mRNA degradation. In cells not expressing the miRNA, stable transgene expression is maintained.
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on the dexamethasone, BCNU, etoposide, ara-C, melphalan regimen.
Combinations with mutDHFR (see above) may be considered for the
treatment of highly aggressive lymphoid malignancies such as B cell
acute lymphocytic leukemias or B-lymphoblastic Non-Hodgkin lym-
phomas, which are routinely treated with combination regimen includ-
ing high-dose methotrexate application.
Potential Side Effects of CDD Gene Therapy
and Strategies to Overcome These
Insertional Mutagenesis
Insertional mutagenesis has been described in several HSC gene ther-
apy studies and clearly represents a major concern for all approaches
using integrating vector systems. This carries a particular relevance
for CDD gene transfer applications as in this setting insertional muta-
genesis may give rise to drug-resistant leukemic cells. In clinical studies,
insertional mutagenesis has been observed specifically for γ-retroviral
constructs expressing the therapeutic gene directly from the strong viral
promoter/enhancer sequences situated in the U3 region of the long
terminal repeat (LTR). In this context, insertion of the vector upstream
of a cellular gene has been observed to lead to an up-regulation of
cellular (onco)genes such as LMO2 or EVI1 mediated by the viral
enhancer [62]. Significant reduction of the mutagenic risk can be
achieved by the use of improved γ-retroviral or lentiviral vector design
such as self-inactivating constructs harboring inactivating deletions in
their 3′LTR U3 promoter/enhancer region and the use of internal pro-
moters derived from housekeeping genes [63]. Our group currently
investigates the potential of such safety-improved constructs in the
context of CDD gene transfer. However, given the risk of generating
CDD-overexpressing leukemic cells, incorporation of inducible suicide
genes such as herpes simplex virus thymidine kinase [64] or a genetically
engineered variant of caspase 9 (i-caspase) [65] into the gene transfer
vectors should be considered as a fail-safe mechanism.
Inadvertent Transduction of Leukemic Cells
As CDD-associated drug resistance primarily is observed for agents
that exert their therapeutic activity in acute leukemias and other hema-
tological malignancies, inadvertent transduction of leukemic cells pres-
ent in the cell preparation used for the ex vivo genetic modification
procedure constitutes another potential problem of CDD gene transfer.
Thus, at present, it appears preferable to use this strategy in combina-
tion with an allogeneic bone marrow transplant approach, as it is state
of the art for high-risk acute myeloid or lymphoid leukemias and
myelodysplasias [66]. If CDD gene transfer is applied in an autologous
setting, again suicide genes may be considered as a fail-safe mechanism.
Cell Type–Specific Toxicities with High
CDD Expression Levels
Another problem encountered in some studies on CDD gene trans-
fer [37] was a lymphotoxic effect associated with high constitutive
CDD expression levels. A potential mechanism for this lymphotoxicity
has been suggested by a recent analysis of mice devoid of deoxycytidine
kinase (dCK) activity, which in the nucleotide salvage pathway rep-
resents the physiologic “counter-enzyme” of CDD, as both, increased
CDD but also reduced dCK activity, directly result in decreased cyti-
dine monophosphate (CMP) levels. Mice deficient in dCK have a block
in intrathymic T as well as early B cell development, indicating a critical
role of the nucleotide salvage pathway during early T and B cell devel-
opment when T cell receptor or VDJ recombination is followed by
massive cellular proliferation and clonal expansion [67]. Furthermore,
a mild to moderate myelotoxicity of CDD overexpression has been
described as most probably related to the negative feedback loop insti-
tuted by the release of high levels of CDD by mature human granulo-
cytes, which in turn inhibits the differentiation and proliferation of
granulocyte-macrophage colony-forming cells and thereby regulates late
steps of myeloid differentiation [21,37]. While cell type–specific toxici-
ties may be ameliorated by CDD expression from suitable internal
promoters such as the truncated human elongation factor 1a or the
SFFV promoter (personal unpublished observation), advanced regu-
lated gene expression systems allowing for inducible (doxycycline-
regulated) or cell type–specific [microRNA (miRNA)-regulated]
expression of the CDD transgene represent another approach to address
this problem. Powerful transcriptionally regulated systems controlled
by the application of doxycycline (also known as tetracycline, Dox)
and allowing for the rapid induction and switch-off of transgene expres-
sion in a tightly controlled fashion have been developed over the last
decade (Figure 4A) [68,69]. An area that appears particularly suited
for the use of this system is the transfer of CTX-R genes for myelopro-
tection, as here transgene expression only is required for the relatively
short periods of cytotoxic drug administration. Thus, toxic effects
associated with prolonged constitutive transgene expression may be
prevented and doxycycline-regulated expression systems already have
been demonstrated to allow for significant CDD overexpression in
the absence of lymphotoxic side effects [39]. In addition, endogenous
miRNAs can be used to target transgenic mRNAs and achieve cell type–
specific transgene expression [70,71].With this approach, miRNA target
sites corresponding to a specific miRNA are added to the transgene-
cDNA rendering the respective mRNA susceptible to miRNA-mediated
degradation selectively in cells that express this miRNA (Figure 4B). In
the context of CDD-induced lymphotoxicity, miRNA-150, which is
predominantly expressed during the late stages of T and B lymphoid
development, may be targeted [72]. However, as the studies in dCK-
deficient mice indicate relatively early stages of T and B lymphopoiesis
as a major target of CDD toxicity, also alternative miRNAs, specifically
expressed at these earlier differentiation stages such asmiRNA-181, may
be exploited [73].
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